MFDS Approves HK Inno.N COVID-19 Vaccine Phase 1 Clinical Trial

Recombinant Vaccines Like Novavax

[Asia Economy Reporter Kim Ji-hee] HK Innoen's COVID-19 vaccine is entering Phase 1 clinical trials.

The Ministry of Food and Drug Safety announced on July 22 that it approved the Phase 1 clinical trial plan to evaluate the safety and immunogenicity of the COVID-19 vaccine candidate 'IN-B009' developed by Innoen. IN-B009 is a 'recombinant vaccine' made using genetic recombination technology to produce the surface antigen protein of the COVID-19 virus.

In particular, a cell-penetrating peptide (CPP) was additionally expressed at the terminal region of the surface antigen protein to facilitate efficient delivery of the protein into cells.

Overseas, companies such as Novavax in the United States are also conducting clinical trials of COVID-19 vaccines using genetic recombination technology.

With this approval, the total number of COVID-19 related clinical trial products being conducted domestically has reached 23, including 10 vaccines and 13 therapeutics (11 active ingredients).

The Ministry of Food and Drug Safety stated, "We will continue to promptly provide information on the status of clinical trials for COVID-19 therapeutics and vaccines, which are of great public interest," and added, "We will do our best to support the development of safe and effective COVID-19 therapeutics and vaccines."

This content was produced with the assistance of AI translation services.